TY - JOUR A2 - Grandone，埃尔维拉AU - 戴维斯，基思L. AU - 蔚蓝，伊莎贝尔AU - 凯伊，詹姆斯A. AU - 门德尔松，艾斯黛拉AU - 高海涛AU - 佩雷斯龙科，朱利安PY - 2015年DA - 2015 /11/09 TI - 848473 VL - - 2015年AB - 真实世界的临床结果与低风险性骨髓纤维化患者接受治疗鲁索利替尼SP评估鲁索利替尼的患者很少有基于试验评估低风险的骨髓纤维化（MF）已进行的，并没有研究在现实世界人口作出这样的评估。我们评估脾脏大小和使用的诊断患有IPSS低危患者匿名美国的医疗记录数据的回顾性，观察检查变更鲁索利替尼治疗期间全身症状（ ñ = 25 ）或中间-1-风险（ ñ = 83 ）MF。大多数的患者是男性（低风险，60％;中间-1风险，69％）。大多数患者（92％和77％），在医疗记录抽象日期（中位数观察/曝光时间，8个月）人仍在接受鲁索利替尼。The proportion of patients with moderate or severe palpable splenomegaly (≥10 cm) decreased from diagnosis (56%) to best response (12%). Fatigue was reported in 47% of patients and was the most common constitutional symptom. For most symptoms in both risk groups, shifts in the distribution of severity from more to less severe from diagnosis to best response were observed. Both patients with low-risk and intermediate-1-risk MF experienced a substantial decrease in spleen size with ruxolitinib treatment in real-world settings. For most symptoms examined, there were distinct improvements in the distribution of severity during ruxolitinib treatment. These findings suggest that patients with lower-risk MF may benefit clinically from ruxolitinib treatment. SN - 1687-9104 UR - https://doi.org/10.1155/2015/848473 DO - 10.1155/2015/848473 JF - Advances in Hematology PB - Hindawi Publishing Corporation KW - ER -